Cargando…

CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial

Expressed by cancer stem cells of various epithelial cell origins, CD133 is an attractive therapeutic target for cancers. Autologous chimeric antigen receptor-modified T-cell directed CD133 (CART-133) was first tested in this trial. The anti-tumor specificity and the postulated toxicities of CART-13...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yao, Chen, Meixia, Wu, Zhiqiang, Tong, Chuan, Dai, Hanren, Guo, Yelei, Liu, Yang, Huang, Jianhua, Lv, Haiyan, Luo, Can, Feng, Kai-chao, Yang, Qing-ming, Li, Xiao-lei, Han, Weidong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993480/ https://www.ncbi.nlm.nih.gov/pubmed/29900044 http://dx.doi.org/10.1080/2162402X.2018.1440169

Ejemplares similares

Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial
por: Dai, Hanren, et al.
Publicado: (2020)

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
por: Jia, Hejin, et al.
Publicado: (2019)

Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo
por: Song, Yanjing, et al.
Publicado: (2017)

PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity
por: Wei, Jianshu, et al.
Publicado: (2019)

Characteristics of premanufacture CD8(+) T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma
por: Wang, Yao, et al.
Publicado: (2023)

Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies
por: Yan, Xin, et al.
Publicado: (2022)

CD58 loss in tumor cells confers functional impairment of CAR T cells
por: Yan, Xin, et al.
Publicado: (2022)

Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
por: Wang, Yao, et al.
Publicado: (2021)

Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial
por: Zhang, Yajing, et al.
Publicado: (2021)

CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma
por: Guo, Yelei, et al.
Publicado: (2022)

Reciprocal activation of antigen-presenting cells and CAR T cells triggers a widespread endogenous anti-tumor immune response through sustained high-level IFNγ production
por: Guo, Yelei, et al.
Publicado: (2023)

Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers
por: Feng, Kaichao, et al.
Publicado: (2017)

CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity
por: Bueno, Clara, et al.
Publicado: (2019)

Clinical development of CAR T cell therapy in China: 2020 update
por: Wei, Jianshu, et al.
Publicado: (2020)

Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia
por: Dai, Hanren, et al.
Publicado: (2015)

Growth of Human Colorectal Cancer SW1116 Cells Is Inhibited by Cytokine-Induced Killer Cells
por: Wang, Yao, et al.
Publicado: (2011)

Prognostic value of CD133(+) CD54(+) CD44(+) circulating tumor cells in colorectal cancer with liver metastasis
por: Fang, Chao, et al.
Publicado: (2017)

New development in CAR-T cell therapy
por: Wang, Zhenguang, et al.
Publicado: (2017)

Challenges and optimal strategies of CAR T therapy for hematological malignancies
por: Zhang, Yajing, et al.
Publicado: (2023)

Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57
por: Zhu, Xuekai, et al.
Publicado: (2014)

Oxytetracycline have the therapeutic efficiency in CD133(+) HCC population through suppression CD133 expression by decreasing of protein stability of CD133
por: Song, Yeonhwa, et al.
Publicado: (2018)

Chromenopyrimidinone Controls Stemness and Malignancy by suppressing CD133 Expression in Hepatocellular Carcinoma
por: Song, Yeonhwa, et al.
Publicado: (2020)

The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies
por: Guo, Zilong, et al.
Publicado: (2021)

Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells
por: Friel, Anne M, et al.
Publicado: (2010)

Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations
por: Grasso, Carole, et al.
Publicado: (2016)

SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies
por: Wei, Wenwen, et al.
Publicado: (2023)

CD133(+)CD54(+)CD44(+) circulating tumor cells as a biomarker of treatment selection and liver metastasis in patients with colorectal cancer
por: Fang, Chao, et al.
Publicado: (2016)

CD133 Expression and Identification of CD133/nestin Positive Cells in Rhabdomyosarcomas and Rhabdomyosarcoma Cell Lines
por: Sana, Jiri, et al.
Publicado: (2011)

CRISPR/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitro
por: Liu, Ming, et al.
Publicado: (2023)

CD133 expression predicts lung metastasis and poor prognosis in osteosarcoma patients: A clinical and experimental study
por: HE, AINA, et al.
Publicado: (2012)

Prostate Cancer Stem Cells: The Role of CD133
por: Yang, Jianhui, et al.
Publicado: (2022)

Differential number of CD34+, CD133+ and CD34+/CD133+ cells in peripheral blood of patients with congestive heart failure
por: Fritzenwanger, M, et al.
Publicado: (2009)

In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133(high) to CD133(low) phenotype and reduces the CD133-related invasiveness
por: Brugnoli, Federica, et al.
Publicado: (2013)

Identification and characterization of CD133(+)CD44(+) cancer stem cells from human laryngeal squamous cell carcinoma cell lines
por: Wang, Jue, et al.
Publicado: (2017)

CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer
por: Nomura, Alice, et al.
Publicado: (2015)

CD133 expression predicts post-operative recurrence in patients with colon cancer with peritoneal metastasis
por: Nagata, Hiroshi, et al.
Publicado: (2018)

Effect of CD133 overexpression on bone metastasis in prostate cancer cell line LNCaP
por: Sohn, Hong Moon, et al.
Publicado: (2019)

CD133 Role in Oral Carcinogenesis
por: Luna, Ealber Carvalho Macedo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r17mc4hqk7njnthjub6g6occ5n